Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1034163 | 0.84 | GPR3 (0.44) | GPR3GAANPC1RAB9AGMNN | |
| SCHEMBL23505696 | 0.82 | ALDH1A1 (0.38) | GAANPC1RAB9AGMNNUSP2 | |
| SCHEMBL442684 | 0.81 | NR4A1 (0.56) | GPR3GAANPC1RAB9AGMNN | |
| SCHEMBL29546263 | 0.81 | NR4A1 (0.56) | GPR3GAANPC1RAB9AGMNN | |
| SCHEMBL29382481 | 0.80 | CYP3A4 (0.45) | GPR3GAANPC1RAB9AGMNN | |
| SCHEMBL1039855 | 0.80 | CYP3A4 (0.45) | GPR3GAANPC1RAB9AGMNN | |
| Hydrochloric Acid SCHEMBL9526864 | 0.79 | NR4A1 (0.54) | GPR3GAANPC1RAB9AGMNN | |
| SCHEMBL15718212 | 0.78 | GPR3 (0.46) | GPR3GAANPC1RAB9AGMNN | |
| SCHEMBL30018924 | 0.78 | GPR3 (0.46) | GPR3GAANPC1RAB9AGMNN | |
| SCHEMBL519232 | 0.78 | ALDH1A1 (0.46) | GPR3GAANPC1RAB9AGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974705-A | Preparation method of 2-bromo-4-trifluoromethoxyaniline | 阜新睿光氟化学有限公司 | 2023-04-18 | — | — | CN | claimed |
| WO-2005100434-A1 | HALOGEN CONTAINING EPOXY COMPOSITIONS AND THEIR PREPARATION | UNIVERSITY OF NORTH TEXAS (US) | 2005-10-27 | — | — | WO | claimed |
| US-20050228080-A1 | Halogen containing epoxy compositions and their preparation | UNIVERSITY OF NORTH TEXAS (US) | 2005-10-13 | — | — | US | claimed |
| EP-3601235-B1 | BICYCLIC HETEROARYL DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | XWPHARMA LTD (KY) | 2026-03-04 | — | — | EP | disclosed |
| US-20260035348-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2026-02-05 | — | — | US | disclosed |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| US-12479802-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ABIVAX (FR) | 2025-11-25 | — | — | US | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| CN-119462748-A | Preparation method of fluorine-containing carbazole phosphonic acid compound | 浙江科技大学 | 2025-02-18 | — | — | CN | disclosed |
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2025-01-30 | — | — | US | disclosed |
| CN-119325476-A | Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-1379755-A | Substituted 2-Dialkylaminoalkylbiphenyl Derivatives | GRUENTHAL GMBH (DE) | 2002-11-13 | — | — | CN | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020147212-A1 | Azabicyclic amine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2002-10-10 | — | — | US | disclosed |
| CN-1356977-A | Glucagon antagonists/inverse agonists | NOVO NORDISK AS (DK) | 2002-07-03 | — | — | CN | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| EP-1045833-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| US-6071927-A | Spiro-piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2000-06-06 | — | — | US | disclosed |
| WO-1999035130-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147212-A1 | Azabicyclic amine derivatives and their use as therapeutic agents | CXCR1, CXCR6, CCR6 | GPR3 268/4885GAA 1432/4885NPC1 1604/4885 |
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP47, USP1 | GPR3 3832/4885GAA 3398/4885NPC1 1789/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | GPR3 1402/4885GAA 3944/4885NPC1 839/4885 |
| US-20260035348-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | SARS1, NDUFC2, CLIC1 | GPR3 3196/4885GAA 2985/4885NPC1 174/4885 |
| US-12479802-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ORC3, NSUN3, POLR2H | GPR3 339/4885GAA 2692/4885NPC1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.